IL114151A - Insulin analog formulations - Google Patents

Insulin analog formulations

Info

Publication number
IL114151A
IL114151A IL11415195A IL11415195A IL114151A IL 114151 A IL114151 A IL 114151A IL 11415195 A IL11415195 A IL 11415195A IL 11415195 A IL11415195 A IL 11415195A IL 114151 A IL114151 A IL 114151A
Authority
IL
Israel
Prior art keywords
insulin analog
analog formulations
formulations
insulin
analog
Prior art date
Application number
IL11415195A
Other languages
English (en)
Other versions
IL114151A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL114151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL114151A0 publication Critical patent/IL114151A0/xx
Publication of IL114151A publication Critical patent/IL114151A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11415195A 1994-06-16 1995-06-14 Insulin analog formulations IL114151A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (2)

Publication Number Publication Date
IL114151A0 IL114151A0 (en) 1995-10-31
IL114151A true IL114151A (en) 2000-09-28

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11415195A IL114151A (en) 1994-06-16 1995-06-14 Insulin analog formulations

Country Status (38)

Country Link
US (1) US5474978A (pt)
JP (2) JP3171541B2 (pt)
KR (1) KR100382326B1 (pt)
CN (1) CN1105576C (pt)
AT (1) AT408720B (pt)
BE (1) BE1009408A5 (pt)
BR (1) BR9502795A (pt)
CA (1) CA2151560C (pt)
CH (2) CH689250A5 (pt)
CO (1) CO4410203A1 (pt)
CZ (1) CZ287484B6 (pt)
DE (1) DE19521720B4 (pt)
DK (1) DK173015B1 (pt)
ES (1) ES2091727B1 (pt)
FI (1) FI118207B (pt)
FR (2) FR2721214B1 (pt)
GB (1) GB2291427B (pt)
GR (1) GR1003004B (pt)
HU (1) HU227240B1 (pt)
IE (1) IE68853B1 (pt)
IL (1) IL114151A (pt)
IT (1) IT1276723B1 (pt)
LU (1) LU88626A1 (pt)
MY (1) MY115631A (pt)
NL (1) NL1000566C2 (pt)
NO (1) NO322128B1 (pt)
NZ (1) NZ272359A (pt)
PE (1) PE19496A1 (pt)
PL (1) PL181310B1 (pt)
PT (1) PT101722B (pt)
RO (1) RO113530B1 (pt)
RS (1) RS49577B (pt)
RU (1) RU2152399C2 (pt)
SE (1) SE509052C2 (pt)
SI (1) SI9500200A (pt)
TW (1) TW421596B (pt)
UA (1) UA26874C2 (pt)
ZA (1) ZA954943B (pt)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
EP0835129B1 (en) * 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
ATE208208T1 (de) * 1996-06-20 2001-11-15 Novo Nordisk As Halogenid-enthaltende insulinzubereitungen
RU2204411C2 (ru) * 1996-06-20 2003-05-20 Ново Нордиск А/С Инсулиновые препараты, содержащие углеводы
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
EA200000453A1 (ru) 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
ES2177323T3 (es) * 1998-10-16 2002-12-01 Novo Nordisk As Preparaciones de insulina concentradas estables para la administracionpor via pulmonar.
EP1121145B1 (en) * 1998-10-16 2002-04-17 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
ATE259653T1 (de) * 1998-11-18 2004-03-15 Novo Nordisk As Stabile wässrige insulinzubereitungen ohne phenol und kresol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US7227033B2 (en) 2002-01-09 2007-06-05 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
RU2202365C2 (ru) * 2001-07-20 2003-04-20 Институт биоорганической химии им. М.М.Шемякина и Ю.А.Овчинникова РАН Способ приготовления быстродействующего раствора инсулина для инъекций
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
CN1836047B (zh) 2003-06-17 2010-12-22 赛姆生物系统遗传公司 在植物中生产胰岛素的方法
DE602004021603D1 (de) * 2003-07-25 2009-07-30 Conjuchem Biotechnologies Inc Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
AU2005209199B2 (en) * 2004-01-16 2008-09-11 Biodel Inc. Sublingual drug delivery device
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
CN102001962B (zh) 2004-05-06 2013-04-03 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
AU2005249410A1 (en) * 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
WO2005115341A2 (en) * 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery
BRPI0513508B1 (pt) 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
CN101014360A (zh) 2004-08-03 2007-08-08 埃米斯菲尔技术公司 抗糖尿病口服胰岛素－双胍组合物
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006124047A2 (en) * 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US7884181B2 (en) * 2004-10-05 2011-02-08 Novo Nordisk A/S Pharmaceutical formulation comprising crystalline insulin and dissolved insulin
ES2391776T3 (es) 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JPWO2006093222A1 (ja) * 2005-03-02 2008-08-07 味の素株式会社 インスリンの多量体形成阻害剤
EP2462944A3 (en) 2005-08-29 2012-09-12 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
PE20100241A1 (es) 2005-09-19 2010-04-16 Emisphere Tech Inc Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20090069216A1 (en) * 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
ES2841379T3 (es) 2007-03-13 2021-07-08 Jds Therapeutics Llc Procedimientos y composiciones para la liberación sostenida de cromo
EP2136624A4 (en) * 2007-03-21 2011-11-30 Emisphere Tech Inc DISPENSER FOR ALLYLOXY- AND ALKYLOXYBENZOIC ACID
WO2008132229A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
JP5868594B2 (ja) 2007-10-16 2016-02-24 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 経口投与可能な固形医薬組成物及びそのプロセス
NZ585080A (en) 2007-11-02 2012-05-25 Emisphere Tech Inc Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
CA2732439A1 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
KR101635689B1 (ko) 2009-01-28 2016-07-01 스마트쎌스, 인크. 제어 약물 전달을 위한 접합체 기재 시스템
MX2011008562A (es) 2009-02-12 2011-09-09 Proyecto Biomedicina Cima Sl Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabolicas.
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
JP2013516500A (ja) 2010-01-11 2013-05-13 ヒールオア・リミテッド 炎症性疾患および障害を治療するための方法
CA2790708A1 (en) * 2010-02-24 2011-09-01 Emisphere Technologies, Inc. Oral b12 therapy
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP6049087B2 (ja) 2010-09-30 2016-12-21 ソルヴェイ（ソシエテ アノニム） 天然起源のエピクロロヒドリンの誘導体
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP2014533241A (ja) 2011-10-27 2014-12-11 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 超濃縮速効型インスリン類似体製剤
WO2014004278A1 (en) * 2012-06-26 2014-01-03 The Curators Of The University Of Missouri Photocleavable drug conjugates
WO2014015078A1 (en) 2012-07-17 2014-01-23 Michael Weiss O-linked carbohydrate-modified insulin analogues
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
US9707275B2 (en) 2012-12-19 2017-07-18 Wockhardt Limited Stable aqueous composition comprising human insulin or an analogue or derivative thereof
JP2016505601A (ja) 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
AR098168A1 (es) 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CA3014308A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
KR20190140048A (ko) 2017-06-01 2019-12-18 일라이 릴리 앤드 캄파니 신속-작용 인슐린 조성물
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
CA3157995A1 (en) 2019-10-25 2021-04-29 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
EP4126058A1 (en) 2020-03-31 2023-02-08 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
KR900701842A (ko) * 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
KR910700262A (ko) * 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) * 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
WO1995000550A1 (en) * 1993-06-21 1995-01-05 Novo Nordisk A/S Aspb28 insulin crystals
CZ287945B6 (cs) * 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina

Also Published As

Publication number Publication date
CA2151560A1 (en) 1995-12-17
HU227240B1 (en) 2010-12-28
CZ287484B6 (en) 2000-12-13
HK1015138A1 (en) 1999-10-08
GB9512038D0 (en) 1995-08-09
NZ272359A (en) 1996-10-28
CZ154295A3 (en) 1996-02-14
GR950100229A (en) 1996-02-29
AT408720B (de) 2002-02-25
FI118207B (fi) 2007-08-31
ITMI951278A0 (it) 1995-06-14
SE9502167D0 (sv) 1995-06-14
FR2741078A1 (fr) 1997-05-16
FR2721214A1 (fr) 1995-12-22
PL309098A1 (en) 1995-12-27
SE509052C2 (sv) 1998-11-30
RU2152399C2 (ru) 2000-07-10
US5474978A (en) 1995-12-12
TW421596B (en) 2001-02-11
DK173015B1 (da) 1999-11-15
RU95110109A (ru) 1997-05-10
CN1105576C (zh) 2003-04-16
GR1003004B (el) 1998-11-05
NO322128B1 (no) 2006-08-21
NO952357D0 (no) 1995-06-14
CH689935A5 (de) 2000-02-15
PT101722B (pt) 1997-02-28
FR2741078B1 (fr) 1998-08-07
YU39695A (sh) 1997-08-22
KR960000924A (ko) 1996-01-25
HU9501716D0 (en) 1995-08-28
LU88626A1 (fr) 1996-02-01
CH689250A5 (de) 1999-01-15
BE1009408A5 (fr) 1997-03-04
MY115631A (en) 2003-08-30
AU2168095A (en) 1996-01-04
IE68853B1 (en) 1996-07-24
JP3171541B2 (ja) 2001-05-28
DK67795A (da) 1995-12-17
ATA101695A (de) 2001-07-15
NL1000566A1 (nl) 1995-12-18
FI952931A0 (fi) 1995-06-14
IE950436A1 (en) 1995-12-27
ZA954943B (en) 1997-09-14
KR100382326B1 (ko) 2003-07-07
SE9502167L (sv) 1995-12-17
RS49577B (sr) 2007-04-10
HUT73186A (en) 1996-06-28
ES2091727A1 (es) 1996-11-01
PT101722A (pt) 1995-12-29
UA26874C2 (uk) 1999-12-29
CO4410203A1 (es) 1997-01-09
GB2291427B (en) 1998-09-16
IT1276723B1 (it) 1997-11-03
SI9500200A (en) 1996-02-29
AU694501B2 (en) 1998-07-23
NL1000566C2 (nl) 1996-12-03
JPH083067A (ja) 1996-01-09
JP2001199899A (ja) 2001-07-24
ITMI951278A1 (it) 1996-12-14
NO952357L (no) 1995-12-18
FR2721214B1 (fr) 1997-09-26
DE19521720A1 (de) 1995-12-21
DE19521720B4 (de) 2009-09-03
IL114151A0 (en) 1995-10-31
CN1122248A (zh) 1996-05-15
BR9502795A (pt) 1996-03-12
RO113530B1 (ro) 1998-08-28
CA2151560C (en) 2000-05-09
PE19496A1 (es) 1996-06-01
ES2091727B1 (es) 1998-02-01
GB2291427A (en) 1996-01-24
FI952931L (fi) 1995-12-17
PL181310B1 (pl) 2001-07-31

Similar Documents

Publication Publication Date Title
GB2291427B (en) Insulin analog formulations
GB2290294B (en) Monomeric insulin analog formulations
IL117696A0 (en) Monomeric insulin analog formulations
AP9500733A0 (en) Pharmaceutical formulations
IL133348A0 (en) Stable insulin formulations
ZA951781B (en) Pharmaceutical formulations
AU731636C (en) Insulin analog formulations
AU694501C (en) Insulin analog formulations
EG26644A (en) Preparations of monoclonal insulin analogs
GB2327424B (en) Monomeric insulin analog formulations
HK1015138B (en) Insulin analog formulations
GB9413542D0 (en) Pharmaceutical formulations
AU2168295A (en) Monomeric insulin analog formulations
AU738101C (en) Monomeric insulin analog formulations
GB9406050D0 (en) Formulations
GB9408419D0 (en) Formulations
GB9409464D0 (en) Formulations
GB9408163D0 (en) Pharmaceutical formulations
GB9401738D0 (en) Pharmaceutical formulations
GB9414216D0 (en) Pharmaceutical formulations
GB9417953D0 (en) Pharmaceutical formulations
GB9426113D0 (en) Pharmaceutical formulations
GB9408151D0 (en) Pharmaceutical formulations
GB9408164D0 (en) Pharmaceutical formulations
ZA953239B (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired